Disclosure forms provided by the authors are available with the full text of this article at

Dr. Nigwekar reports receiving grant support from Sanofi Aventis, Hope Pharmaceuticals, and Allena Pharmaceuticals, and consulting fees from Epizon; Dr. Thadhani, receiving consulting fees from Fresenius Medical Care; and Dr. Brandenburg, receiving grant support paid to the European Calciphylaxis Network (EuCalNet) from Amgen, grant support from Sanifit, Bayer, and Pharmacosmos, and lecture fees from Pfizer. No other potential conflict of interest relevant to this article was reported.

We thank Donald B. Bloch, M.D., Paul R. Conlin, M.D., Kathryn Lucchesi, Ph.D., and James B. Meigs, M.D., for critical review of an earlier version of the manuscript; and Daniela Kroshinsky, M.D., M.P.H., Rosalynn Nazarian, M.D., and Jeremy Goverman, M.D. (all members of the Massachusetts General Hospital’s Multidisciplinary Calciphylaxis Program) for providing clinical images and sharing their viewpoints.

Source: Massachusetts Medical Society: New England Journal of Medicine: Table of Contents